View in EDS

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Saved in:
Bibliographic Details
Title: The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Authors: Hallin J; Mirati Therapeutics, Inc., San Diego, California., Engstrom LD; Mirati Therapeutics, Inc., San Diego, California., Hargis L; Mirati Therapeutics, Inc., San Diego, California., Calinisan A; Mirati Therapeutics, Inc., San Diego, California., Aranda R; Mirati Therapeutics, Inc., San Diego, California., Briere DM; Mirati Therapeutics, Inc., San Diego, California., Sudhakar N; Mirati Therapeutics, Inc., San Diego, California., Bowcut V; Mirati Therapeutics, Inc., San Diego, California., Baer BR; Array BioPharma Inc., Boulder, Colorado., Ballard JA; Array BioPharma Inc., Boulder, Colorado., Burkard MR; Array BioPharma Inc., Boulder, Colorado., Fell JB; Array BioPharma Inc., Boulder, Colorado., Fischer JP; Array BioPharma Inc., Boulder, Colorado., Vigers GP; Array BioPharma Inc., Boulder, Colorado., Xue Y; Memorial Sloan Kettering Cancer Center, New York, New York., Gatto S; Monoceros Biosystems LLC, San Diego, California., Fernandez-Banet J; Monoceros Biosystems LLC, San Diego, California., Pavlicek A; Monoceros Biosystems LLC, San Diego, California., Velastagui K; Mirati Therapeutics, Inc., San Diego, California., Chao RC; Mirati Therapeutics, Inc., San Diego, California., Barton J; Mirati Therapeutics, Inc., San Diego, California., Pierobon M; George Mason University, Manassas, Virginia., Baldelli E; George Mason University, Manassas, Virginia., Patricoin EF 3rd; George Mason University, Manassas, Virginia., Cassidy DP; Dana-Farber Cancer Institute, Boston, Massachusetts., Marx MA; Mirati Therapeutics, Inc., San Diego, California., Rybkin II; Henry Ford Medical Center, Detroit, Michigan., Johnson ML; Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee., Ou SI; University of California, Irvine, Chao Family Comprehensive Cancer Center, Orange, California., Lito P; Memorial Sloan Kettering Cancer Center, New York, New York., Papadopoulos KP; START Center for Cancer Care, San Antonio, Texas., Jänne PA; Dana-Farber Cancer Institute, Boston, Massachusetts., Olson P; Mirati Therapeutics, Inc., San Diego, California., Christensen JG; Mirati Therapeutics, Inc., San Diego, California. christensenj@mirati.com.
Source: Cancer discovery [Cancer Discov] 2020 Jan; Vol. 10 (1), pp. 54-71. Date of Electronic Publication: 2019 Oct 28.
Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-19-1167